[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,965
Citations 0
News From the Food and Drug Administration
October 2, 2018

New Drug Treats Rare, Debilitating Neurotrophic Keratitis

JAMA. 2018;320(13):1309. doi:10.1001/jama.2018.14132

A recently approved drug may offer complete corneal healing for some patients with neurotrophic keratitis.

Cenegermin, which will be marketed as Oxervate, is a topical eye drop. Ophthalmologist Wiley Chambers, MD, of the FDA’s Center for Drug Evaluation and Research, said neurotrophic keratitis can have a devastating effect on patients. “In the past it has often been necessary to turn to surgical interventions; these treatments are usually only palliative in this disease,” Chambers said in a statement, calling cenegermin a “major advance.”